The Impact of SARS-CoV-2 Vaccination and
Infection on Soft Tissue Fillers
ACE Group Guidelines: Dr Martyn King
Introduction cohort of patients that regularly receive
vaccinations, such as the annual influenza
Despite the current low number of reported vaccine, are generally different to the cohort of
cases, reactions caused by mRNA vaccinations patients that undergo soft tissue filler
to SARS-CoV-2 in patients with pre-existing procedures and as the COVID-19 vaccination is
filler is a cause of concern to all aesthetic currently targeting the entire adult population,
practitioners. It is well established in the the incidence of soft tissue filler reactions is
literature, that Delayed Onset Nodules (DONs) likely to rise.
or Delayed Onset Reactions (DORs) can occur
weeks, months or even years after receiving a Mechanism
soft tissue filler treatment when the immune
system is challenged. Potential triggers include It is known that the spike protein of SARS-CoV-
viral illnesses1, bacterial infections (most 2 enters cells by binding and blockade of the
commonly sinus, ear, or dental infections), angiotensin 2 receptors (ACE2) thus creating a
dental procedures2, excessive UV exposure, pro-inflammatory response and a proliferation
subsequent minimally invasive aesthetic of T cells. A study by Li et al (2020) 7
treatments, and vaccinations3. mRNA demonstrated that the skin has moderately
vaccinations are known to be highly high levels of ACE2 proteins in the basal layer
immunogenic4 by increasing protein of the epidermis and also lining the vasculature
translation and modulating innate and which may provide the mechanism to why soft
adaptive immunogenicity, so it is no surprise tissue fillers may react in an adverse manner. It
that they are also capable of activating an is also known that delayed hypersensitivity
immune response in foreign body implants. reactions tend to be T cell mediated rather
However, a study of 106 participants from 18 than due to a B cell antibody response1.
different countries concluded that COVID-19
vaccines did not appear to confer a greater risk Incidence
of a soft tissue reaction than other identified
triggers5. There are currently few published cases that
demonstrate a DON or a DOR following either
Similarly, acute infection with COVID-19 can the COVID-19 vaccination or infection.
also profoundly stimulate the immune system Although due to lockdown restrictions and the
and create a DON or a DOR in a patient who current global vaccination programme, these
has previously undergone a filler treatment. numbers are expected to rise once the number
Current case studies suggest that these of procedures performed escalate to pre-
reactions are more protracted and can be pandemic levels. It is essential that all
more difficult to resolve. practitioners are mindful of this risk, consent
their patients appropriately, risk assess their
Regarding soft tissue swelling following COVID- patients, carefully time their treatments
19 vaccination, this is not unique to these around their expected vaccination date and
vaccines and similar reactions can occur to are knowledgeable on how and when to
many different vaccinations6. However, the intervene if a complication does occur.
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
Signs and Symptoms considers the reaction within 2 weeks of
receiving treatment to be significant. Although
An international consensus group described current evidence is limited, the ACE Group
delayed inflammatory reactions manifesting as recommend that soft tissue filler
discolouration (mostly erythema), painful augmentation should not be performed on any
nodules, induration, tissue hardening and solid patient who is due to receive a mRNA
oedema8. Munavalli et al (2021)9 who reported vaccination within 2 weeks following
on 4 specific cases relevant to this topic treatment. At the time of writing, there are no
included symptoms of significant swelling, documented cases of DONs or DORs with the
burning sensation of the lips, erythema, and non-replicating adenovirus vaccination that is
tenderness. The oedema appeared to coincide used for the Oxford/AstraZeneca COVID-19
with areas of previous filler injections in all vaccination but would also advice caution and
cases. allow a timescale of 2 weeks prior to
vaccination for performing soft tissue
augmentation.
Areas of caution
From studies on other vaccinations, it is known
Although the data is currently extremely
that the immune response from administration
limited, the provisional evidence would
to developing an antibody response that the
suggest that the tear trough, malar and
first 3 weeks are pivotal, and this is when the
perioral regions are most susceptible to DORs 9
immune system is most stimulated. Data from
following COVID-19 infection or vaccination,
Israel in a population of 500,000 has provided
but this may just represent the greater
further evidence. Following the Pfizer vaccine,
frequency that these areas are treated.
immunity within the first 2 weeks of
However, patients that have had lip filler or
administration remained almost at zero but
tear trough treatments in the last 6-12 months
then rose to about 90% at 3 weeks and then
should be considered at a higher risk.
did not rise any further10. For this reason, the
ACE Group recommends that soft tissue filler
Minimising the risk treatments are not performed within 3 weeks
of receiving a vaccine. This guidance would
Before performing any soft tissue filler apply to all current COVID-19 vaccinations.
treatment, the practitioner must take a full
medical history, including previous and recent Although all the current SARS-CoV-2
COVID-19 infection and vaccination schedule. vaccinations do not use live virus for their
Soft tissue filler augmentation is an elective immunogenicity, any patient who is
procedure performed by aesthetic immunocompromised by virtue of a medical
practitioners and, as such, should not interfere condition, medication or undergoing
with patients who are scheduled to undergo oncological treatment should be considered a
SARS-CoV-2 vaccination3. high-risk. Individual risk assessment based on
their medical history should occur, in
The data from the Moderna vaccine trial consultation with their specialist, where
highlighted two cases of facial swelling and one appropriate.
case of angioderma in patients who had
previously had soft tissue fillers in these areas. Previous soft tissue filler treatments are not a
One had treatment within 2 weeks, one within contra-indication to vaccination and these
6 months and one unreported. Given the study patients should be encouraged to be
population of 15,184 patients and the vaccinated but advised to contact their
incidence of facial filler treatments, it is likely healthcare practitioner if they do develop
that a significant number of these patients some facial swelling following the vaccine11.
would have had treatment within the last 12
months. For this reason, the ACE Group
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
Consent response following the vaccination but quickly
subside without treatment. However, if the
Although the incidence is very low, it is response is greater than expected or lasts
important that patients are fully aware of any more than a few days, the evidence suggests
risks related to COVID-19 infection or that a short course of corticosteroids 3 is likely
vaccination and soft tissue fillers. The ACE to manage the complication quickly. The ACE
Group emphasises that this should be included Group recommends a dose of 40mg oral
on consent forms: Prednisolone for a duration of 5 days. As an
alternative, Dexamethasone 5mg orally for 3
days can be used. Dexamethasone has a longer
Although there is limited evidence and only a half-life of 36-72 hours (compared to
very small number of cases, there is a risk of prednisolone which has a half-life of 18-36
inflammatory reactions and soft tissue swelling hours).
in patients who have previously had soft tissue
fillers, or plan to have treatment, after There are concerns between the medical
receiving COVID-19 vaccination. society and patients that the administration of
oral corticosteroids may affect mounting an
Do not undergo soft tissue filler procedures effective immune response to SARS-CoV-2. The
within 2 weeks of your planned vaccination prescribing practitioner must consider the
date or within 3 weeks having received it. seriousness of the DOR and the individual’s
medical history before issuing any medication.
Do not attend for treatment if you have Immune response is based on many criteria
symptoms consistent with COVID-19 or are including age, health, lifestyle factors, medical
suffering from ongoing symptoms from history, and concomitant medication.
previous infection.
Doses of Prednisolone above 20mg per day (or
If you develop any reactions following your 2mg/kg) for 2 or more weeks or more are
treatment, it is imperative you contact your sufficiently immunosuppressive to warrant
healthcare practitioner at the earliest concerns about live vaccinations12, however
opportunity. steroid therapies that are short term (less than
2 weeks), alternative day, physiological
If you develop any reactions following your replacement or topical/aerosol are not contra-
treatment, you may require medication to indications. Although, the response to vaccines
manage the complication. This may include may be suboptimal.
oral steroid medication which may lower your
immunity to COVID-19 if you have recently If the DON or DOR that occurs because of
been vaccinated. COVID-19 vaccination does not respond as
expected, practitioners should follow the
guidelines for COVID-19 infection.
Treatment of DONs and DORs Treatment of DONs and DORs
caused by COVID-19 vaccination caused by COVID-19 infection
The current evidence would suggest that acute
It would initially be prudent to treat the acute
DORs in patients with soft tissue fillers
inflammatory response the same as treating
presents as mild to moderate oedema, which
the reaction to a SARS-CoV-2 vaccination as
is sometimes associated with erythema and
this may resolve the situation in a swift and
tenderness, although cases of angioedema
uncomplicated manner. However, from the
have also been reported. These reactions are
limited evidence available, patients who
often spontaneous and self-limiting3 and are
contract COVID-19 and develop a DON or DOR
likely to be due to the heightened immune
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
tend to have a more recalcitrant problem ACE inhibitors and ARB (Angiotensin II
needing multiple interventions. Receptor Blockers) in the treatment of COVID-
19 and its complications. The single case report
If there is minimal response to an initial course in the aesthetics journals, whereby a single
of oral corticosteroids, or the problem case responded quickly (likely spontaneous
escalates, the ACE Group recommends a resolution based on the timescale), the ACE
prescription of a tetracycline (such as Group cannot recommend this as a potential
Doxycycline 100mg BD or Minocycline 100mg treatment at this time.
BD)13. These agents not only have antibiotic
properties but also anti-inflammatory and anti- Anti-Histamines
humoral activity. If the patient is allergic to
tetracyclines or there are other contra- The mechanism of immune response following
indications, a macrolide (such as a DON or a DOR is likely to be a Type IV delayed
Clarithromycin 500mg BD) should be hypersensitivity reaction, mediated by a T-
considered. Response to treatment should be lymphocyte response. However, even though
assessed and dual therapy considered. Type IV immunogenic reactions are
unresponsive to anti-histamines14, there have
Depending on response, hyaluronidase should been reported cases of improvement following
be considered for hyaluronic acid dermal fillers the administration of anti-histamines6. Due to
whilst remaining on antibiotic cover. The the low risk of adverse events related to the
dosage used will depend on the extent and size prescribing of anti-histamines and the small,
of nodules and the filler product used, but will but possible, risk of advantageous outcomes,
usually be between 500 to 1000 units, injected the ACE Group suggests consideration of the
directly into the nodules to infiltrate and use of an oral anti-histamine in the case of a
disperse them and at multiple depths and recalcitrant DON or DOR following COVID-19
angles of injection. Follow up and assessment infection or vaccination.
must be undertaken, and hyaluronidase may
be repeated up to three times at suitable
Other Aesthetic Procedures
intervals.
There is currently no evidence that COVID-19
For cases failing to respond or for non-
vaccination or infection has a detrimental
hyaluronic acid fillers, there is evidence for the
effect on other aesthetic procedures, including
injection of intralesional steroids (such as
botulinum toxin. However, as patients may
triamcinolone acetonide or
become unwell and experience flu-like
methylprednisolone acetate) and anti-mitotic
symptoms following vaccination, the ACE
agents (such as 5-fluorouracil)13. These drugs
Group recommends avoiding treatments for 1
should be used at a suitable concentration and
week post vaccine.
volume and gradually increased according to
response. The ACE Group recommends that
only practitioners familiar with these agents Reporting
and competent at managing complications
should consider these treatments and less There is a distinct lack of reporting of
experienced practitioners should refer. complications in aesthetic practice. The ACE
Group advocates that all practitioners should
Angiotensin Converting Enzyme report complications to the manufacturers and
the MHRA. The ACE Group also provides a
Inhibitors (ACE Inhibitors) reporting mechanism to facilitate this process
via the website and App. Due to the lack of
Due to the mechanism of action of the SARS- evidence concerning COVID-19 vaccine and
CoV-2 virus penetrating cell membranes by infection, it is even more important that
accessing the ACE2 receptor mechanism, reporting occurs. The MHRA have created a
research has been conducted into the use of
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
dedicated Coronavirus Yellow Card reporting
site which should be used: 2. More severe, acute reactions, such as
angioedema, should be managed
https://coronavirus-yellowcard.mhra.gov.uk/ according to the severity although a short
course of moderate to high dose
Key Points: corticosteroids, with or without anti-
histamines, is likely to bring a speedy
1. Acute soft tissue reactions following mRNA resolution to the problem.
vaccination, including oedema, erythema,
and tenderness, appear to be very low in 3. Considering this evidence, patients need to
number, relatively mild and self-limiting. understand the potential risks of soft
Adopting a watchful waiting approach may tissue filler treatments around
be the sensible option, especially as vaccinations and infections and this should
treating with oral corticosteroids may be part of the screening and consent
impair the immune response to the process.
vaccine.
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
References
1. Turkmani, M.G., De Boulle, K. and Philipp-Dormston, W.G. (2019). Delayed hypersensitivity
reaction to hyaluronic acid dermal filler following influenza-like illness. Clinical, Cosmetic and
Investigational Dermatology, Volume 12, pp.277–283.
2. Beleznay, K., Carruthers, J.D.A., Carruthers, A., Mummert, M.E. and Humphrey, S. (2015). Delayed-
Onset Nodules Secondary to a Smooth Cohesive 20 mg/mL Hyaluronic Acid Filler. Dermatologic
Surgery, 41(8), pp.929–939.
3. American Society for Dermatologic Surgery Guidance Regarding SARS-CoV-2 mRNA Vaccine Side
Effects in Dermal Filler Patients. (n.d.). [online]. Available at:
https://www.asds.net/Portals/0/PDF/secure/ASDS-SARS-CoV-2-Vaccine-Guidance.pdf. [Accessed
6 Mar. 2021].
4. Pardi, N., Hogan, M.J., Porter, F.W. and Weissman, D. (2018). mRNA vaccines — a new era in
vaccinology. Nature Reviews Drug Discovery, [online] 17(4), pp.261–279. Available at:
https://www.nature.com/articles/nrd.2017.243.
5. Gotkin, R.H., Gout, U., Sattler, S., Piansay-Soriano, M.E., Wanitphakdeedecha, R., Ghannam, S.,
Rossi, E., Ferrariz, T.S., Hexsel, D., Frank, K., Davidovic, K., Sarnoff, D.S. and Cotofana, S. (2021).
Global Recommendations on COVID-19 Vaccines and Soft Tissue Filler Reactions: A Survey-Based
Investigation in Cooperation With the International Society for Dermatologic and Aesthetic
Surgery (ISDS). J Drugs Dermatol, 20(4): doi:10.36849/JDD.2021.6041
6. Health.com. (n.d.). 3 People in Moderna’s Vaccine Trial Experienced Side Effects Due to Facial
Fillers. [online] Available at: https://www.health.com/condition/infectious-
diseases/coronavirus/moderna-vaccine-facial-filler [Accessed 6 Mar. 2021].
7. Li, M.-Y., Li, L., Zhang, Y. and Wang, X.-S. (2020). Expression of the SARS-CoV-2 cell receptor gene
ACE2 in a wide variety of human tissues. Infectious Diseases of Poverty, 9(1).
8. Artzi, O., Cohen, J.L., Dover, J.S., Suwanchinda, A., Pavicic, T., Landau, M., Goodman, G.J.,
Ghannam, S., Al Niaimi, F., van Loghem, J.A., Goldie, K., Sattler, S., Cassuto, D., Lim, T.S.,
Wanitphakdeedecha, R., Verner, I., Fischer, T.C., Bucay, V., Sprecher, E. and Shalmon, D. (2020).
Delayed Inflammatory Reactions to Hyaluronic Acid Fillers: A Literature Review and Proposed
Treatment Algorithm. Clinical, Cosmetic and Investigational Dermatology, Volume 13, pp.371–
378.
9. Munavalli, G.G., Guthridge, R., Knutsen-Larson, S., Brodsky, A., Matthew, E. and Landau, M.
(2021). “COVID-19/SARS-CoV-2 virus spike protein-related delayed inflammatory reaction to
hyaluronic acid dermal fillers: a challenging clinical conundrum in diagnosis and
treatment.” Archives of Dermatological Research.
10. BBC Science Focus Magazine. (n.d.). Pfizer vaccine: Single dose “90 per cent effective after 21
days.” [online] Available at: https://www.sciencefocus.com/news/pfizer-vaccine-single-dose-90-
per-cent-effective-after-21-days [Accessed 6 Mar. 2021].
11. www.cdc.gov. (2020). Interim Clinical Considerations for Use of Pfizer-BioNTech COVID-19
Vaccine | CDC. [online] Available at: https://www.cdc.gov/vaccines/covid-19/info-by-
product/clinical-considerations.html. [Accessed 6 Mar. 2021].
12. www.paho.org. (n.d.). Immunization Newsletter, v.32, n.4, Aug.2010 - PAHO/WHO | Pan
American Health Organization. [online] Available at:
https://www.paho.org/en/documents/immunization-newsletter-v32-n4-aug2010 [Accessed 6
Mar. 2021].
13. King, M., Bassett, S., Davies, E., & King, S. (2016). Management of Delayed Onset Nodules. The
Journal of clinical and aesthetic dermatology, 9(11), E1–E5.
14. Funt, D. and Pavicic, T. (2015). Dermal Fillers in Aesthetics. Plastic Surgical Nursing, 35(1), pp.13–
32.
The Impact of SARS-CoV-2 Vaccination and Infection on Soft Tissue Fillers
© ACE Group World, Dr Martyn King, Published 6th March 2021
